Experimental cancer drug tested in advanced tumors – study halted early
NCT ID NCT03144661
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 28 times
Summary
This early-stage study tested an experimental drug called INCB062079 in 25 people with advanced liver cancer (hepatocellular carcinoma) and several other solid tumors. The main goal was to check the drug's safety and find the highest dose people could tolerate. The study was terminated early, so results are limited.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
-
Institut Jules Bordet
Brussels, 1000, Belgium
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
University Hospital (UZ) Leuven
Leuven, 3000, Belgium
-
University of Alabama
Birmingham, Alabama, 35294, United States
-
University of Toledo Medical Center
Toledo, Ohio, 43614, United States
Conditions
Explore the condition pages connected to this study.